TLL-018 not checked
Hangzhou Highlightll Pharmaceutical Co., Ltd · Sequence 1 · Sequence 2
FollowEvery change as it happens, and a Monday email
Trials
6 active
12 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Oral Placebo tablets taken orally 1 pieces BlD for 12 weeks and then Oral TLL-018 tablets taken orally 1 pieces BlD for 40 weeks.”In the company’s words, NCT06396026 on ClinicalTrials.gov
- Tested for
- Chronic Spontaneous Urticaria (CSU) (2 trials), Chronic Spontaneous Urticaria, Rheumatoid Arthritis, Atopic Dermatitis (AD), Rheumatoid Arthritis (RA)
- Main trialPhase 3
- “A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TLL-018 in Participants With Moderate-to-Severe Chronic Spontaneous Urticaria (CSU) With Inadequate Controll to Second Generation H1-antihistamines.”In the company’s words, NCT06396026 on ClinicalTrials.gov
- Other names
- Sequence 1 · Sequence 2 · Sequence 3 · extended-release tablet · immediate-release tablet
Other drugs for Chronic Spontaneous Urticaria (CSU)
- RemibrutinibNovartis Pharmaceuticals · Phase 3
- MG-K10Shanghai Mabgeek Biotech.Co.Ltd · Phase 3
- JYB1904Jemincare · Phase 3
- LP-003Longbio Pharma · Phase 3
- BarzolvolimabCelldex Therapeutics · Phase 3
- ICP-332Beijing InnoCare Pharma Tech Co., Ltd. · Phase 2/3
Coming up5
- 31 DecPhase 3 trial completes · ClinicalTrials.gov
- 31 Jul 2027Phase 2 trial completes · ClinicalTrials.gov
- 31 Dec 2027Phase 2 trial completes · ClinicalTrials.gov
- 31 Dec 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 30 Sep 2029Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials12
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 23 Oct 2025 | A Study of Efficacy and Safety of TLL-018 in CSU Participants | |
| Phase 3Active, not recruiting | 31 Dec 2026 | A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis | |
| Phase 2/3Not yet recruiting | 30 Sep 2029 | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profiles of TLL-018 in Patients With Moderate-to-Severe Atopic Dermatitis | |
| Phase 2Enrolling by invitation | 31 Jul 2027 | TLL-018 in Patients With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to csDMARDs | |
| Phase 2Not yet recruiting | 31 Dec 2027 | A Study of Efficacy and Safety of TLL-018 in CSU Participants With Inadequate Response to 2nd-generation H1-AHs | |
| Phase 1/2Not yet recruiting | 31 Dec 2027 | A Phase Ib/IIa Study Assessing the Rapid Onset Characteristics of TLL-018 for Moderate-to-Severe CSU With Inadequate Response to Second-Generation H1 Antihistamines | |
| Phase 3Completed | 15 Jan 2026 | A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs | |
| Phase 2Completed | 19 Dec 2022 | The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis | |
| Phase 2Completed | 1 Dec 2024 | The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis | |
| Phase 1Completed | 28 Aug 2023 | Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects | |
| Phase 1Completed | 30 Aug 2023 | Safety and Efficacy of TLL018 in Patients With Plaque Psoriasis | |
| Phase 1Completed | 7 Sep 2023 | Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026